The National Cancer Institute: cancer drug discovery and development program.

New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening

1990 • 9,412 citations

Induction of Chronic Myelogenous Leukemia in Mice by the P210 ^bcr/abl Gene of the Philadelphia Chromosome

1990 • 2,207 citations

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

1990 • 1,308 citations

Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products

1990 • 1,305 citations

Display and Analysis of Patterns of Differential Activity of Drugs Against Human Tumor Cell Lines: Development of Mean Graph and COMPARE Algorithm

1989 • 943 citations

THE IMPACT OF NATIONAL CANCER ACT

1991 • 809 citations

Acute leukaemia in bcr/abl transgenic mice

1990 • 701 citations

New Soluble-Formazan Assay for HIV-1 Cytopathic Effects: Application to High-Flux Screening of Synthetic and Natural Products for AIDS-Antiviral Activity

1989 • 689 citations

DNA Topoisomerase I—Targeted Chemotherapy of Human Colon Cancer in Xenografts

1989 • 645 citations

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

1990 • 535 citations

Design, Activity, and 2.8 Å Crystal Structure of a C ₂ Symmetric Inhibitor Complexed to HIV-1 Protease

1990 • 524 citations

BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner

1991 • 375 citations

Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data

1991 • 363 citations

Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent

1991 • 324 citations

An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.

1990 • 234 citations

Potential roles for preclinical pharmacology in phase I clinical trials.

1986 • 213 citations

Pharmacologically Guided Phase I Clinical Trials Based Upon Preclinical Drug Development

1990 • 208 citations

Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition.

1992 • 177 citations

Discovery and Development of Antineoplastic Agents from Natural Sources

1989 • 153 citations

Overlapping cDNA clones define the complete coding region for the P210c-abl gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chromosome.

1986 • 138 citations

Inhibition of type II topoisomerase by fostriecin

1988 • 116 citations

Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate.

1990 • 112 citations

Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase.

1980 • 112 citations

Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene.

1991 • 89 citations

The preclinical new drug research program of the National Cancer Institute.

1984 • 85 citations

Relation of preclinical toxicology to findings in early clinical trials.

1986 • 73 citations

Opportunities for Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development

1992 • 61 citations

In Vitro activity of the novel antitumor antibiotic fostriecin (CI-920) in a human tumor cloning assay

1986 • 53 citations

In Defense of Cell-Line Screening

1990 • 30 citations

Preclinical antitumor activity of an alpha-picoline derivative, penclomedine (NSC 338720), on human and murine tumors.

1989 • 24 citations

Computer-aided selection of compounds for antitumor screening: validation of a statistical-heuristic method

1981 • 16 citations

Drug development for cancer: Implications for chemical modifiers

1989 • 10 citations

The efficacy of animal studies in predicting clinical toxicity of cancer chemotherapeutic drugs.

1973 • 9 citations